newsfilter
← Latest News
GlobeNewswire·

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

  • Beam Therapeutics Inc. appointed Eric Foster as chief commercial officer on September 1, 2026.
  • Foster will lead the company's commercial organization & strategy as it advances product candidates in hematology & genetic disease franchises.
  • John Evans, CEO, highlighted Foster's 25+ years of experience, including building successful rare disease franchises at Horizon Therapeutics prior to its 2023 acquisition by Amgen.
  • Prior to joining Beam, Foster served as chief commercial officer at Ardelyx & senior vice president at Amgen managing gout & ophthalmology units that generated $2.75 billion in net sales.
  • Foster previously held senior sales & marketing roles at GlaxoSmithKline from 2010 to 2021 & began his career at Johnson & Johnson.
  • Beam anticipates a potential launch of its product candidate risto-cel in 2027, a timeline where Foster's leadership will be utilized.
  • The company utilizes base editing technology to enable precise single base changes in targeted genomic sequences without DNA double-stranded breaks.
  • Forward-looking statements in the release include risks regarding regulatory approval, clinical trial timing, manufacturing, & commercial infrastructure scaling.